To evaluate which drug is better in terms of relieving pain either dexmedetomidine or nalbuphine when given in supraclavicular plexus block in upper limb orthopaedic surgeries.

Comparison of nalbuphine and dexmedetomidine as an adjuvant to 0.5% ropivacaine in USG guided supraclavicular plexus block in upper limb surgeries: A randomised double blind prospective study. - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/03/082843

Enrollment

100

Registered

2025-03-19

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M848- Other disorders of continuity of bone

Interventions

Intervention1: Nalbuphine: 25 ml of ropivacaine 0.5 % + 1ml(10mg) nalbuphine Control Intervention1: Dexmedetomidine: 25 ml of ropivacaine 0.5 % + 1 ml (100 mcg) dexmedetomidine

Eligibility

Inclusion criteria

Inclusion criteria: ASA grade 1 and 2, of both gender, age group of 18-60 years, scheduled for various orthopedic surgeries of upper limb (around elbow and forearm surgeries) under supraclavicular brachial plexus block.

Exclusion criteria

Exclusion criteria: Having known hypersensitivity to local anesthetic drugs, bleeding disorders, pre-existing neuropathy,infection at nerve block site, any hepatic, renal, neurological, psychiatric, or neuromuscular diseases, pregnant and lactating females

Design outcomes

Primary

Measure	Time frame
To compare the time of onset and duration of sensory and motor block among the ropivacaine-dexmedetomidine and ropivacaine-nalbuphine groups.Timepoint: upto 24 hours of drug administration	—

Secondary

Measure	Time frame
To evaluate the incidence of side effects in each group.Timepoint: upto 24 hours of drug administration	—

Countries

India

Contacts

Public ContactSunny

AIIMS Raebareli

AGGARWALSUNNY87@GMAIL.COM8259064008

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026